NEWS 22 FEED & ADDITIVE MAGAZINE June 2024 The CEO of MicroBioGen, an Australian industrial biotechnology company and provider of ‘Yeast Innovation as a Service’, presented on opportunities for producing sustainable, alternative aquafeed using yeast technology, at international aquaculture conference, Aqua Farm 2024. MicroBioGen CEO Geoff Bell discussed how the company’s innovative yeast platform technology, based on improving the industrial capabilities of the yeast Saccharomyces cerevisiae, can be leveraged to transform industrial waste and side streams into valuable single cell protein (SCP), optimised as a fishmeal replacement. Bell presented on day one of the event in the Innovative Alternative Proteins session and joined the subsequent panel discussion. As the global demand for protein continues to rise, so does the demand for fish. With wild fish stocks declining, aquaculture is expanding to fill the gap. Current aquafeeds rely heavily on fishmeal as the main protein component. However, fishmeal as an ingredient for aquafeed is unsustainable, and there is a need for more environmentally friendly protein substitutes that have comparable nutritional value, MicroBioGen states. MicroBioGen’s innovative non-GM yeast technology offers a groundbreaking solution in transforming large-scale industrial waste and side streams into sustainable, high-quality protein. The company continues by explaining that this technology harnesses waste products such as glycerol, organic acids, and residual sugars from ethanol and biodiesel production, as well as lactose from dairy processing, to produce bioavailable protein for fish and animal feeds, thereby promoting environmental sustainability and economic efficiency in aquaculture. In developing a protein rich SCP alternative to fishmeal that can be produced from abundant waste products, the company states that its breakthrough provides a cost-effective, scalable solution to fortify aquafeeds with sustainably sourced, high-quality protein. Additional benefits include a balanced amino acid profile and higher levels of natural, beneficial enzymes that aid in the absorption of nutrients. “For nearly two decades, MicroBioGen has developed yeast technology for industrial purposes aimed at improving our partners and their customers’ process efficiency, economics and sustainability. Here, we enable the transformation of what was once low- and negative-value waste into a high-quality protein that can serve as a fishmeal replacement. In short, we help global industries make more with less, in a more efficient and sustainable way,” says Geoff Bell, CEO and co-founder at MicroBioGen Read more>> MicroBioGen highlights yeast SCP The U.S. Food and Drug Administration (FDA) has confirmed that Bovaer meets safety and efficacy requirements for use in lactating dairy cattle. Elanco Animal Health Incorporated, which has made an agreement with dsm-firmenich to expand distribution of the product across North America to include the Canadian and Mexican markets, expects the product launch in Q3 2024. “This monumental announcement has the ability to accelerate the opportunity for climate-neutral dairy farming while creating a new revenue stream for dairy farmers across the country,” said Jeff Simmons, President and CEO, Elanco Animal Health. “We appreciate FDA’s commitment to maintaining Elanco agrees with dsm-firmenich for Bovaer's North American distribution
RkJQdWJsaXNoZXIy MTUxNjkxNQ==